Abstract
Sonidegib, a hedgehog pathway inhibitor, was approved by the US FDA for the treatment of locally advanced basal cell carcinoma which cannot be readily treated with surgery or radiotherapy. The pharmacology and pharmacokinetics of sonidegib will be discussed in this review. Additionally, an in-depth analysis of the BOLT trial and data from the 30-month update will be included. This will serve as an update to a previously published article which reported the 12-month update of the BOLT trial.
Keywords:
BOLT; HPI; basal cell carcinoma; hedgehog pathway inhibitor; laBCC; locally advanced basal cell carcinoma; mBCC; metastatic basal cell carcinoma; sonidegib.
Publication types
-
Clinical Trial, Phase II
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Biphenyl Compounds / administration & dosage
-
Biphenyl Compounds / adverse effects
-
Biphenyl Compounds / therapeutic use*
-
Carcinoma, Basal Cell / drug therapy*
-
Carcinoma, Basal Cell / pathology*
-
Follow-Up Studies
-
Humans
-
Molecular Targeted Therapy
-
Pyridines / administration & dosage
-
Pyridines / adverse effects
-
Pyridines / therapeutic use*
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / pathology*
-
Treatment Outcome
Substances
-
Antineoplastic Agents
-
Biphenyl Compounds
-
Pyridines
-
sonidegib